Figure 8.

Nanoparticle-based delivery to various biological barriers and specific cancers, including (A) blood–brain barrier-penetrating nanoparticles utilizing the PLGA-b-PEG-TPP polymer and the incorporated CoQ₁₀ and aspirin prodrug for the treatment of brain cancers and associated conditions; (B) prostate-cancer-targeting nanoparticle delivery of the cisplatin prodrug using the interaction between the GLU peptide incorporated into the polymer and PSMA expressed on prostate cancer cells; (C) gut-epithelium-targeting nanoplatform for the oral delivery of various drugs into the bloodstream via FcRn-mediated uptake; and (D) proposed liver-cancer-targeting nanoformulation with blended ligand-containing polymers.